SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eisai Says Leqembi Cut Alzheimer’s Progression Risk 36% Versus ADNI

A five-year study reported a 36% reduction in Alzheimer’s progression risk with Leqembi versus ADNI.

BIIB

Story updates

11:01:52 PM UTC
SquawkNews
Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over timeLecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at fiv…
11:02:01 PM UTC
SquawkNews
Biogen and Eisai reported five-year Clarity AD extension findings: lecanemab reduced relative risk of progression to the next disease stage by 36% versus ADNI. In the study, 62% of low-tau patients showed improvement on CDR-SB at five years.Material DetailsContext by AI AnalystThis is long-term fol…

Related stories